TRANSFORM - Observational Cohort Study of Darbepoetin Alfa Use in European Union (EU) Hemodialysis Patients Switched From PEG Epoetin Beta

CompletedOBSERVATIONAL
Enrollment

1,027

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

July 31, 2013

Conditions
Anemia
Trial Locations (32)

1950

Research Site, Sion

2650

Research Site, Edegem

11528

Research Site, Athens

15000

Research Site, Aurillac

15562

Research Site, Athens

15701

Research Site, Santiago de Compostela

15706

Research Site, Santiago de Compostela

15993

Research Site, Ribeira

24106

Research Site, Kiel

33505

Research Site, Libourne

34500

Research Site, Béziers

34790

Research Site, Grabels

41000

Research Site, Blois

42270

Research Site, Saint-Priest-en-Jarez

44606

Research Site, Saint-Nazaire

46000

Research Site, Cahors

48527

Research Site, Nordhorn

54270

Research Site, Essey-lès-Nancy

54504

Research Site, Vandœuvre-lès-Nancy

57000

Research Site, Metz

59800

Research Site, Lille

62200

Research Site, Boulogne-sur-Mer

67000

Research Site, Strasbourg

75015

Research Site, Paris

75016

Research Site, Paris

85925

Research Site, La Roche-sur-Yon

86021

Research Site, Poitiers

92160

Research Site, Antony

97400

Research Site, Saint-Denis de La Réunion

97410

Research Site, Saint-Pierre

97420

Research Site, La Réunion

6815 AD

Research Site, Arnhem

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01997892 - TRANSFORM - Observational Cohort Study of Darbepoetin Alfa Use in European Union (EU) Hemodialysis Patients Switched From PEG Epoetin Beta | Biotech Hunter | Biotech Hunter